Recombinant glucagon: a differential biological activity by Angelina M M Basso et al.
Basso et al. AMB Express  (2015) 5:20 
DOI 10.1186/s13568-015-0099-2ORIGINAL ARTICLE Open AccessRecombinant glucagon: a differential biological
activity
Angelina M M Basso1,2, Patrícia B Pelegrini2, Fernanda Mulinari2,3, Michelle C Costa2, Antonio B Viana2,4, Luciano P Silva5
and Maria Fatima Grossi-de-Sa2,4*Abstract
In Brazil, there is a growing demand for specialised pharmaceuticals, and the high cost of their importation results
in increasing costs, reaching US$ 1.34 billion in 2012 and US$ 1.61 billion in 2013. Worldwide expenses related to
drugs could reach US$ 1.3 trillion in 2018, especially due to new treatments for hepatitis C and cancer. Specialised
or high-cost pharmaceutical drugs used for the treatment of viral hepatitis, multiple sclerosis, HIV and diabetes are
distributed free of charge by the Brazilian government. The glucagon peptide was included in this group of high-cost
biopharmaceuticals in 2008. Although its main application is the treatment of hypoglycaemia in diabetic patients, it
can also be used with patients in an alcoholic coma, for those patients with biliary tract pain, and as a bronchodilator.
Therefore, in order to reduce biopharmaceutical production costs, the Brazilian government passed laws focusing on
the development and increase of a National Pharmaceutical Industrial Centre, including the demand for the national
production of glucagon. For that reason and given the importance and high cost of recombinant glucagon, the
purpose of this study was to develop methods to improve production, purification and performance of the biological
activity of recombinant glucagon. Glucagon was recombined into a plasmid vector containing a Glutathione S-transferase
tag, and the peptide was expressed in a heterologous Escherichia coli system. After purification procedures and molecular
analyses, the biological activity of this recombinant glucagon was examined using in vivo assays and showed a highly
significant (p < 0.00001) and prolonged effect on glucose levels when compared with the standard glucagon. The
experimental procedure described here facilitates the high level production of recombinant glucagon with an extended
biological activity.
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The development of recombinant proteins has been
extremely promising. In 2009, pharmaceutical industries
spent US$ 90 billion on the activity evaluation of 400
different drugs. Moreover, in 2012, more than 150
recombinant drugs were approved by FDA (Food and
Drug Administration) regulators and/or by the European
Medicine Agency (Huang et al. 2012). By 2017, it is
expected that over 300 products will be in the biopharma-
ceutical market, with a value of about US$ 109 billion
and an expected growth of US$ 166 billion (Ibarra
Cabrera et al. 2013). Worldwide expenses related to drugs* Correspondence: fatima.grossi@embrapa.br
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in any medium, provided the original work is pcould reach US$ 1.3 trillion in 2018, especially due to new
treatments for hepatitis C and cancer (Chen, 2014).
According to the World Health Organization, one
third of the world’s population has no regular access to
essential medicines (Nowbike 2006; Blatt et al. 2012). In
Brazil, the Government provides free, high-cost drugs to
the population, which are classified into three different
categories: basic, strategic and specialised. The specialised
components are expensive, which limits access of the
population to important medicines. Hence, in 1993, the
Program for Specialized Medicaments (SM) became a
prospective solution to this problem. However, most of
these medicines are imported from other countries,
resulting in a large cost to the Brazilian government.
Moreover, the expectation is that the amount spent
on the importation of SM will continue to grow over
the next several years.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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drugs, which is four times the amount (US$ 198 million)
spent in 2003 (Valadares 2009). In 2013, US$ 1.61 billion
was spent, and in 2014, preliminary data were provided
by the Brazilian Ministry of Health showing US$ 1.5
billion for the purchase of SM (Brazil Ministry Health,
2014). Therefore, to reduce high costs associated
with imported pharmaceutical products, the Brazilian
government released the Technological Innovation Law,
which stimulates the development of new biotechnological
companies for the production of national biopharmaceuti-
cals (Brazil Ministry Health 2008; de Castro 2014). The
Technological Innovation Law is part of a strategic plan to
strengthen the pharmaceutical industry, due the increased
demand for health public services and consumption
(medicines, diagnostics kits, vaccines, etc.). The strategy
aimed to replace the imported drugs that were causing a
significant impact on the economy and encourage
scientific training and public–private partnerships
(Victora et al. 2011; Silveira 2012; Reddy 2013; Sund-
feld and Souza 2013). In 2012, 34 public–private partner-
ships were developed to produce several molecules with
therapeutic activity, such as anti-retroviral and anti-
asthmatic drugs and drugs used to treat rheumatoid arth-
ritis and Crohn and Gaucher diseases, among others
(Paiva 2012). In 2013, 63 public-private partnerships were
developed, resulting in the production of 63 drugs,
vaccines and rapid diagnostic tests, involving 16 public
and 41 private laboratories, with an estimated US$ 2.8 bil-
lion per year in budget savings (Oliveira 2013). Alongside
Brazil, other countries, such as South Korea and India,
also used national biosimilar production as an alternative
to increase the access of high-cost biopharmaceuticals to
the population (IMS 2011) through similar biotechnology.
Furthermore, the large accumulation of expired patents re-
lated to biopharmaceutical products led to the development
of a second generation of drugs: biosimilars (Niederwieser
and Schmitz 2010; Utzig et al. 2010). The substitution of
classic drugs with biosimilars depends on the criteria estab-
lished by each country (Rosenberg et al. 2010).
The glucagon peptide could be used in diagnostics tests
or for the treatment of alcoholic coma, biliary tract pain,
hypoglycaemia (as a bronchodilator), etc. (Guimarães et al.
2011). Furthermore, glucagon has been on the Brazilian
SM Program list since 2008. Currently, glucagon is
imported from other countries, and initial production of
new substances is restricted to universities and research
centres (Massi et al. 2013). The main activity of glucagon
involves the primary regulation of glucose production
in the liver in situations of fasting, exercise and
hypoglycaemia (Ramnanan et al. 2011). Hancock and col-
leagues (2010) indicated that the main glucagon activity
was associated with glycemic control in fasting and post-
prandial situations. Therefore, glucagon utilisation isimportant since this hormone shows a fundamental role
in glycemic control and, consequently, the maintenance of
homeostasis.
In this work, the glucagon peptide was expressed and
purified from Escherichia coli cells using the pGEX vector
system. An efficient purification procedure at the laboratory
scale for a biologically active Glutathione S-transferase
(GST)-glucagon fusion molecule was also performed. The
biological activity of the biosimilar molecule was evaluated
in in vivo tests, showing a prolonged activity when
compared with the control (Glucagen NovoNordisk®).
This study is the first report in which glucagon is efficiently
produced in Brazil using a bacterial system, showing
advanced biological activity in in vivo assays.
Materials and methods
Materials
Glucagon PCR primers were purchased from Integrated
DNA Technologies (Coralville, IA, USA) and the FUSION
Taq High-Fidelity enzyme was purchased from Finnzymes,
Thermo Scientific (Vantaa, Finland). The glucagon expres-
sion vector pGEX4t-3 and the Glutathione Sepharose 4
Fast Flow resin were purchased from GE Healthcare (Inc,
Sweden). E. coli BL21 (DE3) cells (Invitrogen) were kindly
provided by Embrapa Cenargen, Brazil. The expression
inductor Isopropyl β-D-1-thiogalactopyranoside (IPTG)
was acquired from Invitrogen (Carlsbad, CA., USA).
Glucagen®, used as positive control, was obtained from
Novo Nordisk A/S (Denmark). Polyclonal anti-glucagon
antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA., USA).
Cloning of the human glucagon gene
The nucleotide sequence of human glucagon (GenBank
GI 30582464), containing 128 bp, was cloned into the
synthetic vector pGEX4t-3 (GE Healthcare). The glucagon
coding sequence was then amplified using designed
primers containing a Sal I site (forward - 5’ GGG GGT
CGA CGATTA CAA AGATGATGATG 3’), a Not I site
(reverse – 5’ TTT TGC GGC CGC TCA GGT GTT CAT
CAG CCA C 3’) and a cleavage site for the FLAG tag. The
amplicon was purified, and a recombination reaction was
performed to clone the glucagon fragment into the
pGEX4-t3 expression vector (GE Healthcare). The re-
combinant plasmid was used to transform E. coli
XLI-Blue cells via electroporation, and transformed cells
were initially selected using LB (Luria and Bertani) agar
plates [1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5%
(w/v) sodium chloride, and 1.5% (w/v) agar, supplemented
with 100 μg/mL ampicillin, pH 7.0].
Recombinant glucagon expression
The construct was inserted into E. coli BL21 (DE3)
cells through thermal shock. To evaluate the glucagon
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10 mL of LB medium containing ampicillin (100 μg/mL)
and grown overnight at 37°C (200 rpm). The seed culture
was inoculated into 1 L (Litre) of LB medium supplemented
with ampicillin, and cells were grown at 30°C during 2
hours. The expression induction was carried out by the
addition of IPTG (Isopropyl β-D-1-thiogalactopyranosid;
0.25 mM). After 4 hours of induction, cells were harvested
by centrifugation (1680 g for 5 min at 25°C). The super-
natant was discarded, and the pellet was resuspended in 1X
sample buffer [10% glycerol (w/v), 2-10% mercaptoethanol
(v/v), 2.3% sodium dodecyl sulfate (w/v), 124 mM Tris-
Base, 0.01% bromophenol blue (w/v)] and boiled for 5 min.
After that, soluble and insoluble proteins were separated by
centrifugation (13171 g for 5 min), and protein molecular
masses were analysed by Coomassie-blue stained,
12.5% acrylamide SDS-PAGE gels (Sambrook and Russell
2006). Glucagon expression levels were determined by
densitometry using the ImageScannerIII (GE Healthcare
Inc., Sweden) and ImageMaster2D Plattinum 7.02 and
LabScan 6.0 (GE Healthcare Inc., Sweden) software for
data analyses.
Bioreactor glucagon expression was performed. Larger
lab-scale peptide production was obtained using the
Wave Bioreactor™ 20/50 EHT system (GE Healthcare,
Brazil). A series of parameters were adjusted to optimise
glucagon expression in the Wave Bioreactor, such as the
swing angle (30°), speed (30 rpm), temperature (30°C)
and airflow (0.1 ppm for 30 seconds every 1 hour).
Peptide expression was induced with the addition of
IPTG (0.25 mM), and cells were harvested after 4 hours.
Glucagon purification
Recombinant glucagon was purified by Glutathione
Sepharose 4 Fast Flow (GE Healthcare Inc., Sweden)
affinity chromatography according to the manufacturer’s
instructions. Purified samples were dialysed overnight in a
tube with a cut off of 12000–14000 kDa (Cheshire
Sciences, UK), lyophilised and stored at −20°C for
quantification. Each sample concentration was previously
estimated using Qubit methodology (Invitrogen, USA).
Quantified samples were used for the digestion procedure
with enterokinase.
Western blot assays
Purified GST-FLAG-Glucagon and non-purified protein
concentrations were estimated using the Bradford
method (1976). Protein molecular mass was estimated as
previously described. Glucagon was detected using the
polyclonal anti-glucagon antibody (Santa Cruz, CA., USA)
and alkaline phosphatase-conjugated anti-goat IgG (GE
Healthcare Inc., Sweden). The Alkaline Phosphatase
Conjugate Substrate Kit (BioRad, CA., USA) was used
according to the manufacturer’s instructions.Cleavage of the fusion protein
The cleavage reaction for the fusion protein was performed
using the enzyme enterokinase EKMax (Invitrogen, USA)
at a concentration of 1 U per 20 μg of purified recombinant
peptide and incubated at 22°C overnight. A 7-16%
Tris-Tricine gel (Schangger 2006) was used to analyse
the cleavage reaction.
Protein sequencing
After cleavage, the GST-FLAG and Glucagon proteins
were diluted in 0.1% trifluoroacetic acid and purified by
reverse-phase ultra fast high performance liquid chroma-
tography (RP-UFLC) (RP-UFLC LC-20 AD/T LPGE kit,
Shimadzu Corporation Kyoto, Japan) using a Vydac
C-18TP column. Retained proteins were eluted with a
linear gradient of acetonitrile (0-100%). Samples were
then subjected to speed-vac concentration, and major
fractions were mixed with a saturated matrix solution
of alpha-cyano-4-hydroxycinnamic acid (1:3) and spotted
(0.5 μl) onto an MTP AnchoChip var/384 matrix-assisted
laser desorption ionisation (MALDI) target plate. The
monoisotopic molecular mass of glucagon was determined
by MALDI-time of flight TOF/MS tandem mass spectrom-
etry (MALDI-TOF/MS) using an AutoFlex Speed (Bruker
Daltonics, Germany) controlled by the FlexControl 3.0
software. The MS spectra were acquired in the positive ion
reflector mode at a laser frequency of 100 Hz, and the MS/
MS spectra were obtained by LIFTTM mode, both with
external calibration using the peptide calibration standard I
(Bruker Daltonics, Germany). Data were analysed using the
Flex-Analysis 3.0 software.
In vivo bioassays
In vivo bioassays were performed following the method-
ology described by Hinke et al. (2000) with modifications.
Briefly, recombinant glucagon (7.1 nmol/kg), commercial
glucagon (positive control) and dH2O (negative control)
were injected into three groups of five male Wistar rats,
respectively. After administration, glucose levels were
monitored at 0, 10, 20 and 40 minutes. The differences in
glucose levels (differences between 10, 20 or 40 minutes
and the baseline time) over time were calculated and
evaluated. When the recombinant glucagon was used, the
blood glucose level was maintained at a 1.3-fold increased
level 40 minutes after injection, whereas it decreased to
similar levels as the negative control after 40 minutes
when the commercial glucagon was used. The biological
test was repeated three times.
In this study, to biological assay the initial samples
contained recombinant glucagon with a FLAG-GST tag.
The fusion between FLAG-GSTand recombinant glucagon
was removed from digestion with enterokinase. After this
step, samples were evaluated for in vivo biological activity.
The FLAG-GST tag and recombinant glucagon were in
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fusioned.
The study was previously approved by the Pioneer
Union for Social Insertion – UPIS Committee for Ethical
Use of Animals (CEUA), and the proposal (#071-11)
entitled “Biological activity evaluation of recombinant
peptide glucagon” was approved on August 12, 2011.
Therefore, the reported experimental procedures comply
with ethical procedures for animal use in in vivo experi-
ments (Ellery 1985).
Statistical analyses were based on the generalised linear
mixed model test (R Development Core Team 2010) and
were used to validate the differences between values
obtained by the different groups. In addition, analyses
were performed to assign a fold-difference value com-
paring the increased glycemic levels seen at 10, 20
and 40 minutes with the basal levels, considering the
random variation of rats. P < 0.05 was considered sta-
tistically significant. R statistical packages were used
to validate the data.
Results
Glucagon expression and purification
After expression, it was observed that 40 to 50% of
total soluble product corresponded to the glucagonFigure 1 Recombinant glucagon peptide expression profiling and analy
protein expression using 1 L of culture media; Lower lane: protein expression
Lanes 2 to 9 indicate expression protein patterns after 0 h, 1 h, 2 h, 3 h, 4 h, 5
glucagon using anti-glucagon antibodies. Lane 1: Pre-Stained Protein Ladder
non-digested glucagon fused with the GST protein (3 μg) arrows indicate rec
separate the peptide from the GST tag in Tris-Tricine gel. Lane 1: Seeblue Plus
glucagon fused with the GST protein (5 μg); Lane 3: Pre-Stained Protein Ladd
5 μg); Lane 5: digested glucagon (40 μg total digestion).peptide, which, including the GST fusion protein, pre-
sented a molecular mass of 31.44 kDa (Figure 1A;
Additional file 1: Figure S1). After purification using
affinity chromatography, densitometry analyses indi-
cated that the GST-glucagon corresponded to 90% of
the purified product. Western blotting assays using
both anti-GST and anti-glucagon antibodies confirmed
the presence of the GST-fused glucagon (Figure 1B).
Later, the cleavage of glucagon from the GST fusion
protein using the enterokinase enzyme produced a
3.5 kDa-peptide, as revealed by a 16% Tris-tricine gel
(Figure 1C).
Amino acid sequencing of glucagon
After hydrolysis, the glucagon peptide was purified using
UFLC (ultra-high performance liquid chromatography),
and fractions were collected. The ion corresponding to the
peptide was present in a fraction that eluted at 26 minutes
of separation, and it was further detected by MALDI-TOF
(Matrix Assisted Laser Desorption Ionisation Time-of-
Flight) MS (Additional file 2: Figure S2). Hence, 16
amino acid residues from the N-terminus of glucagon
(H-S-Q-G-T-F-T-S-D-Y-S-K-Y-L-D-S) were determined
by de novo sequencing, indicating that the predicted
digestion was performed as expected.sis. (A) Glucagon expression after different incubation times. Upper lane:
in the bioreactor (5 L). Lane 1: BenchMark Protein Ladder (Invitrogen);
h, 6 h and overnight incubation, respectively. (B) Western blotting of
(Invitrogen); Lane 2: purified GST protein (3 μg); Lane 3 purified
ombinant glucagon fused with GST protein. (C) Glucagon digestion to
2 Pre Stained Standard (Invitrogen); Lane 2: purified non-digested
er (Invitrogen); Lane 4: commercial glucagon (Glucagen, NovoNordisk,
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GST-Glucagon activity was evaluated by measuring
glycemic levels in rats before and after exposure to
the glucagon molecule. Both the recombinant peptide and
the commercially available glucagon (NovoNordisk®)
induced a similar blood glucose peak right after injection.
Nevertheless, the recombinant glucagon maintained blood
glucose levels at a 1.3-fold increased level 40 minutes after
injection, whereas commercial glucagon decreased to
the same levels of negative control after 40 minutes
(Additional file 3: Figure S3). Statistical analyses demon-
strated that the differential time profile of glucose levels
between the recombinant glucagon and the commercial
glucagon was significant (Figure 2A-C).Glucagon expression using the WAVE Bioreactor
To evaluate the expression level of recombinant glucagon
at a higher scale with controlled conditions, the WAVE
bioreactor (GE Healthcare) was used at a scale up of
5 L (Figure 1A, lower lane). After expression andFigure 2 Statistical model analysis of the biological activity test
based on glucose levels during specific times after of samples
administration. (A) Negative control. (B) Positive control.
(C) Recombinant glucagon. p > 0,00001.purification, the final yield of recombinant glucagon
in the bioreactor reached 7 mg/L.
Discussion
Among the seven emerging countries in the biopharma-
ceutical market (Russia, China, Turkey, Mexico, South
Korea, India and Brazil), a growth from US$ 5.3 billion in
2010 to US$ 13.6 billion in 2015 is estimated (International
Market Analysis Research & Consulting, 2010). Biosimilar
sales are expected to reach between US$ 1.9 - 2.6 billion
(IMS 2011) in 2015. In 2016, the medicines market will
spend US$ 1.2 trillion, most of which are expenses focused
on cancer, diabetes and asthma drugs (IMS Institute 2012).
The cost of drugs used for diabetes treatment (insulin,
glucagon, and others) reached US$ 548 billion in 2013.
In the United States, it is estimated that the diabetes
drug market will expand by about US$ 125 million
(Biodel 2013; Hassan et al. 2014). Statistical data suggest
a worldwide growth from 382 million diabetic people
in 2013 to 592 billion people in 2035 (Ledford 2013;
Guariguata et al. 2014). There is an estimated 200.000
people/year that are hospitalised due to severe
hypoglycaemia, and only 20% of this number use the
glucagon emergency kit. One of the main causes for the
lack of access to the kit is the elevated price (Biodel 2013).
The first glucagon recombinant regimen was created by the
NovoNordisk® Company in 1989 using a yeast heterologous
system (Saccharomyces cerevisiae) (patent n°4.826.763). In
1994, the Eli Lilly® Company used an E. coli heterologous
system to produce recombinant glucagon (patent n°
5.512.549). Today, recombinant glucagon is expressed in
many countries for high scale production purposes, mainly
own production (Agarwal et al. 2014) and such that is
reported by When and colleagues (2001).
The glucagon production reached 40 to 50% of the
total protein expression, with concentrations slightly
above the 39% reported by Ohana and colleagues (2011),
which evaluated different protein expression yields with
differential tag systems. The tac promoter (de Boer et al.
1983) used in the expression vector contributed to the
high level of glucagon production. It is already known that
the tac promoter is strong and one of the most widely
used in research and industry (Huang et al. 2012).
Bioreactors have been used in the recombinant peptide
industry for more than a decade, mainly due to the flexi-
bility of use reducing costs, labour and contaminations.
However, the major limitations are the amount of oxygen
used during expression and the low refrigeration capacity
(Dreher et al. 2014). An initial peptide expression in
bioreactors was also performed using up to 5 L of culture
media. The ultimate goal of establishing a methodology
for producing biopharmaceuticals is scale-up. Hence, the
expression yielded 122 mg of semi-purified peptide, a
3.4-fold increase compared with the expected value
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suggested that the expression of glucagon in bioreactors
using bacterial cells might provide better conditions for
peptide production, indicating that the methodology used
can easily be applied at industrial levels.
It is estimated that 77% of E. coli expression proteins
are insoluble (Cuozzo and Soutter 2014). However, some
studies showed high levels of soluble peptide production
when fused with tag proteins, such as Thioredoxin (Trx)
and GST (Gao et al. 2010). Hence, the glucagon peptide
was expressed in the soluble phase partly due to the
addition of a GST tag. At the end of the process, achieving
satisfactory amounts of protein does not mean success
(Rosano and Ceccarelli 2014). It is necessary to evaluate the
biological activity to validate the process (Nausch et al.
2013). Here, we demonstrate that the recombinant
GST-glucagon displayed high glycemic levels for a
longer period of time than the commercial glucagon.
For a biosimilar, it was expected that recombinant gluca-
gon here produced and the positive control (commercial
glucagon) should demonstrate similar glucose levels dur-
ing the evaluated time, which was not observed in this
study.
The analysis of recombinant proteins fused with GST
in biological assays has been earlier described, with no
interference of the targeted protein's activity. Recently,
two antitumoral proteins, granzyme B (GrB) and
perforin (PFP), earlier known by their ability to inhibit
cell viability, were cloned into the pGEX-4 T-1 vector
and expressed in bacterial systems. The fusion proteins
GST-GrB and GST-PFP were later challenged against Hep-
2 cells, showing significant decreases in laryngeal cancer
cell growth (Li et al. 2014). Using GST as a control, the
assay also demonstrated the inability of the fusion protein
to interfere with recombinant protein activities.
Therefore, the application of bacterial systems for the
expression of human peptides fused with GST proteins is
becoming a promising strategy in the production of re-
combinant molecules with potential for biopharmaceutical
products. A previous report showed that a recombinant
glucagon-like peptide-1 analogue (KGLP-1), also used onTable 1 Technologies used in the process to obtain recombin
Technology Patent number
pGEX4t-3 t vector US 5654176
GST Tag US 5654176
FLAG Tag US 4703004
BL21(DE3) strain US 5693489
Enterokinase Enzyme US 5665566
Glutathione Sepharore Resin US 5654176
Glucagen® US 5652216
*The first patent filed was in 1989. This is an evergreening patent, a type of patent wdiabetes therapy, was expressed in E. coli cells as a fusion
protein with GST (Liu et al. 2014). In this study, digestion
reactions were performed to remove GST from glucagon
and confirmed by Tris-Tricine gel (Figure 1C). Furthermore,
in biological activity, the recombinant glucagon in the
presence of GST tag, but not fused to it, showed prolonged
high glycemic levels when compared with the positive con-
trol (Glucagen® NovoNordisk). The removal of tags from
recombinant proteins is also critical, as it may interfere with
the shape and activity of the protein of interest. Moreover,
recombinant proteins with permanent tags are not allowed
by the standards of therapeutic proteins (Walls et al. 2011;
Einsfrldt et al. 2011). Therefore, the GST tag was removed
from the fusion with the peptide glucagon using enteroki-
nase. According to Hosfield and Lu (1999), enterokinase
presents a cleavage efficiency, when the first amino acid
residue of a protein fused with flag-tag is histidine, which is
the case of recombinant glucagon, the cleavage efficiency of
enterokinase is 74%. Moreover, according to Kahn (2009),
of the 29 amino residues, the first amino acids close to the
N-terminal portion are essential for biological activity,
mainly histidine (position 1), asparagine (position 9) and
serine (position 16). If glucagon was fused to GST, the histi-
dine amino acid could not be connected to the glucagon re-
ceptor, and the biological activity would be partially
impaired, which was not observed here.
All patents of technologies used in this work (Table 1)
were deposited in 1997. Thereby, the patents expire in
2017, allowing the use of this protocol to obtain recom-
binant glucagon. The estimated value spent (Table 2,
Additional file 4: Table S1) per mg of recombinant
glucagon in this work was US$ 175.28. However, this
value can be reduced to US$ 22.10 (see Table 2). In
Brazil, the commercial value of recombinant glucagon is
US$ 56.60, 2.5 times more expensive than recombinant
glucagon. This value can be changed because the recom-
binant glucagon was semi-purified and total purification
can increase the value.
In this work, the glucagon peptide was expressed in a
soluble form using a pGEX vector in a bacterial system,
yielding a high concentration of the purified product.ant glucagon and respective patents








ith novel technology is added to previous one. Basso (2012)
Table 2 Products used for recombinant glucagon expression and respective costs for 1 litre expression
Product Price (US$) Amount used Final price spent (US$)
Ampicillin 134.33 100 mg 2.68
Benzamidine 207.92 180.225 mg 7.49
Enterokinase 1 781.50 1U/20 μg fusioned protein 1094.11*
Enterokinase 2 781.50 1U/1 mg fusion protein 21.87*
Yeast extract 56.60 5 g 1.14
Reduced glutathione 6135.00 3.07 g 14.21
IPTG 86.03 59.57 mg 5.12
KCl 47.54 3 mg 0.0002
KH2PO4 107.54 3.67 mg 0.007
NaCl 47.54 5.12 g 0.97
Na2HPO4 125.29 21.29 mg 0.005
PMSF 181.13 261.29 mg 9.46
Tips 16.98 15 units 0.25
Glutathione Sepharose 1864.90 4 mL 74.59
Tryptone 128.31 10 g 5.14
TrisHCl 93.59 6.05 g 2.26
Water, equipment and others 9.53
Total with enterokinase 1 1226.96 (**/7 = 175.28)
Total with enterokinase 2 157.72 (**/7 = 20.10)
Prices obtained from the companies Invitrogen, GE and Sigma. *Value may change depending on the concentration used for digestion. In this work, we used
manufacturer’s instructions (1U/20 μg), but literature reports (Ehrhardt et al. 2000; SUN et al. 2011) indicate 1U/mg recombinant protein to digestion. Thereby,
this concentration was used to calculate this value in this condition. **Total value divided by 7, the recombinant protein total obtained in the 1 litre expression
(7 mg in 1 litre) to indicate the value for 1 mg. Basso (2012)
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tiated activity on glycemic levels when compared with
the positive control, in the presence but not fused to
the GST-tag. Further studies aimed to better understand
the cause of this extended effect on glycemic levels and
the role of GST are being performed.
Many recombinant biopharmaceuticals have been
developed for use in biotechnology. However, after the
expiration of several pharmaceutical patents, a variety
of biosimilars have been produced. Some strategies are
emerging for protein production at a large-scale to ob-
tain higher levels of expression. Hence, in this report,
we describe, for the first time, the production of the bio-
similar glucagon hormone in a heterologous system by
a Brazilian research group. Moreover, an improved ex-
pression and purification of the peptide is reported,
which could support, in the future, the treatment of pa-
tients with several different diseases and will decrease
Brazilian importation costs with medicaments. Further-
more, local production of the biosimilar glucagon will
stimulate the development of national pharmaceutical
industries. The peptide in the presence of GST, but not
fused, showed a prolonged activity when compared with
the positive control. This differential activity may be
beneficial because it reduces the discomfort caused by
the increase and decrease of glucose levels aftercommercial drug administration. However, further studies
will indicate potential adverse effects of recombinant
glucagon.
Additional files
Additional file 1: Figure S1. Recombinant glucagon peptide expression
profiling. Soluble and insoluble expression of the glucagon samples. Lanes 1
and 6: Prestained SDS-PAGE Standards Low Range (Bio-Rad); Lane 2:
Expression of the soluble glucagon; Lane 3: soluble fraction of expressed
proteins in a non-induced sample; Lane 4: insoluble fraction of expressed
glucagon; Lane 5: insoluble fraction of expressed proteins in a non-induced
sample; Arrows indicate recombinant glucagon fused with the GST protein.
Additional file 2: Figure S2. Mass spectrometry sequencing using
MALDI-TOF/TOF (LIFTTM mode). Sequencing part of the fraction of the
1991.83 Da of the glucagon peptide showing the N-terminal portion (y)
starting from amino acid H(y1) and reverse sequencing (b) starting from
amino acid Q (b2) (despite the absence of b1, the same reveals its presence
in y series). The calibrant used the peptide calibration standard II Mixture
(Bruker Daltonics), detection range m/z 1000–4000. The analysed fraction
retention time was 26 min.
Additional file 3: Figure S3. Analysis of glycemic levels using the
in vivo biological activity test. This assay used four times (0, 10, 20 and
40 minutes after sample administration). Positive control (Glucagen®
NovoNordisk), Negative control (dH2O).
Additional file 4: Table S1. Apparatus used for recombinant glucagon
and costs for 1litre expression.
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